Additionally, blast percentage criteria variances led to diagnostic discrepancies between MDS and AML, such as AML with CEBPA mutations (≥10% blasts in ICC; ≥20% in WHO-2022 criteria) or AML with mutated NPM1 (≥10% blasts in ICC; increased blasts percentage in WHO-2022 criteria). The gene discussed is CEBPA; the disease is intrahepatic cholangiocarcinoma.